Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer cachexia.

Marcus E Martignoni1, Philipp Kunze, Helmut Friess

  • 1Department of General Surgery, University of Heidelberg, Im Neuenheimer Feld 110 Germany. me.martignoni@med.uni-heidelberg.de

Molecular Cancer
|November 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRG1 promotes hepatocarcinogenesis by regulating proliferation and invasiveness.

PloS one·2017
Same author

R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer.

Annals of surgery·2017
Same author

Mobile Health in Oncology: A Patient Survey About App-Assisted Cancer Care.

JMIR mHealth and uHealth·2017
Same author

Different regimens of perioperative chemotherapy for esophagogastric and gastric adenocarcinoma: does a triplet therapy with taxane generate a survival benefit?

Translational gastroenterology and hepatology·2017
Same author

The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.

Cancer treatment reviews·2017
Same author

The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.

Surgical oncology·2017
Same journal

Correction: Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer.

Molecular cancer·2026
Same journal

IL-17-driven tumor cell-intrinsic inflammatory programming creates an immunotherapy-permissive microenvironment.

Molecular cancer·2026
Same journal

Dissecting oral premalignant carcinogenesis: spatial omics mechanisms and nanomedicine-driven therapeutic innovation.

Molecular cancer·2026
Same journal

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Molecular cancer·2026
Same journal

The role of the WD40-repeat protein family in cancer.

Molecular cancer·2026
Same journal

Correction: Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Molecular cancer·2026
See all related articles

Cachexia is a serious condition causing weight loss and weakness, affecting many diseases including cancer. This editorial focuses on cancer-related cachexia, a syndrome that worsens patient prognosis.

Area of Science:

  • Oncology
  • Internal Medicine
  • Pathophysiology

Background:

  • Cachexia syndrome, characterized by abnormal weight loss and weakness, impacts patients with various chronic and end-stage diseases.
  • Conditions associated with cachexia include cancer, AIDS, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, tuberculosis, and Crohn's disease.
  • Cachexia significantly deteriorates patients' quality of life and reduces their prognosis.

Discussion:

  • This editorial specifically addresses cancer-related cachexia.
  • It aims to provide insights into the mechanisms and clinical implications of this prognosis-limiting syndrome in cancer patients.

Key Insights:

  • Cachexia is a multifactorial condition associated with significant morbidity and mortality.
  • Understanding cachexia in cancer is crucial for improving patient outcomes.

Related Experiment Videos

  • Early recognition and management strategies are vital.

    • Outlook:

    • Further research is needed to elucidate the complex pathophysiology of cachexia.
    • Developing targeted therapies for cancer-related cachexia is a priority.
    • Improving the quality of life and survival rates for cachectic cancer patients remains a key goal.